Impact of adalimumab treatment on impairment of non‐professional activities in psoriasis patients

Summary Background and objectives Psoriasis can result in reduced quality of life, work productivity loss, and a significant restriction in non‐professional activities. This study investigates the effects of long‐term treatment with adalimumab regarding work ability, non‐professional activities, and health‐related quality of life in a large real‐word population in Germany. Patients and methods Single‐arm, multicenter non‐interventional study to document routine care data for up to 5 years in adult patients with psoriasis after initiation of adalimumab. Results Baseline data was collected for 4,793 (62.1 % male) patients with a mean (± SD) age of 47.5 ± 13.11 years. The number of days with restrictions in non‐professional activities was much higher than in professional activities. Under adalimumab, the psoriasis‐related number of days unfit for work and number of days with restrictions in non‐professional activities significantly decreased. Correlation analyses showed that psoriatic arthritis, disease severity (PASI > 10), and impairment of quality of life (DLQI > 10) are associated with restrictions in non‐professional activities. Health‐related quality of life improved over the observed time but remained reduced in patients with restrictions in non‐professional activities. Conclusions Long‐term treatment with adalimumab had a favorable impact on clinical outcomes, employment‐related aspects, practice of non‐professional activities, and health‐related quality of life in psoriasis patients.